<i>In situ</i>vaccine application of inactivated CPMV nanoparticles for cancer immunotherapy
Paul L. Chariou, Veronique Beiss, Yifeng Ma, Nicole F. Steinmetz
Abstract
assay indicated activation of the RAW-Blue™ reporter cells by formaldehyde and UV-inactivated CPMV at levels comparable to native CPMV; βPL-inactivated CPMV appeared to have diminished activity. Tumor mouse model experiments indicate potent efficacy of the chemically-inactivated CPMV (UV-treated CPMV was not tested) leading to tumor regression and increased survival; efficacy was somewhat reduced when compared to CPMV, however these samples outperformed the empty CPMV nanoparticles. These results will facilitate the translational development of safe and potent CPMV-based cancer immunotherapies.
Topics & Concepts
Cancer immunotherapyImmunotherapyIn situMedicineCancerChemistryInternal medicineOrganic chemistryTransgenic Plants and ApplicationsViral gastroenteritis research and epidemiologyBacteriophages and microbial interactions